title: Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy.
authors.affiliation: Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.
authors.forename: Elvis
authors.initials: E
authors.lastname: Aduwa
authors.forename: Richard
authors.initials: R
authors.lastname: Szydlo
authors.forename: David
authors.initials: D
authors.lastname: Marin
authors.forename: Letizia
authors.initials: L
authors.lastname: Foroni
authors.forename: Alistair
authors.initials: A
authors.lastname: Reid
authors.forename: John
authors.initials: J
authors.lastname: Goldman
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.forename: Dragana
authors.initials: D
authors.lastname: Milojkovic
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides; D015992:Body Mass Index; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate